Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer.
Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer.
复制标题
无细胞循环甲基化 SEPT9 用于结直肠癌的无创诊断和监测
DOI：
10.1155/2018/6437104
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Liu W
中科院分区：
文献类型：
--
作者：
Fu B;Yan P;Zhang S;Lu Y;Pan L;Tang W;Chen S;Chen S;Zhang A;Liu W
及时发现早期肿瘤、监测治疗效果和复发转移是改善结直肠癌患者预后、降低疾病相关死亡率的迫切需要。在这项研究中，我们评估了无细胞循环甲基化SEPT 9（mSEPT 9）对CRC和结直肠癌以外的诊断价值，并检查了mSEPT 9在评估治疗效果和监测结直肠癌复发方面的潜力。我们的研究结果证实了血浆mSEPT 9对结直肠癌的良好诊断价值，采用2/3算法，其敏感性为61.22%（95%CI：51.33%-70.27%），特异性为93.7%（95%CI：91.09%-95.57%）。mSEPT 9在结直肠癌组织中的阳性表达率与肿瘤大小、组织学分级及一般组织学类型有关（P < 0.05）。除CRC外，胃癌患者的血浆mSEPT 9阳性率也很高（70%）。术前和术后血浆mSEPT 9之间的转换反映了CRC患者的治愈性预期手术的治疗效果。手术后血浆mSEPT 9的持续阳性（7-14天内）与即将发生的复发或转移（1年内）高度相关，灵敏度为100%。随访期间的术后mSEPT 9状态也为CRC复发或转移提供了有价值的指示，具有良好的一致性（kappa = 0.818，P = 0.001）。我们的结果验证了血浆mSEPT 9作为CRC非侵入性诊断生物标志物的可靠性。更重要的是，我们揭示了它在评估结直肠癌治疗效果和监测结直肠癌复发或转移方面的价值。需要更大样本量的进一步研究来验证和阐明这些有希望的发现的临床实用性。
Identification of early-stage tumor and monitoring therapeutic efficacy and recurrence or metastasis of colorectal cancer (CRC) are urgently warranted for improving the outcome of CRC patients and reducing the disease-related mortality. In this study, we evaluated the diagnostic value of cell-free circulating methylated SEPT9 (mSEPT9) for CRC and beyond CRC and examined the potentiality of mSEPT9 in assessing therapeutic efficacy and monitoring recurrence of CRC. Our results confirmed the favorable diagnostic value of plasma mSEPT9 for CRC, with a sensitivity of 61.22% (95% confidence interval (CI): 51.33%–70.27%) and specificity of 93.7% (95% CI: 91.09%–95.57%) using 2/3 algorithm. The positive rate of mSEPT9 in CRC was correlated with tumor size, histological grade, and general histological type (P < 0.05). Beyond CRC, gastric cancer patients also presented a high positive rate of plasma mSEPT9 (70%). The conversions between preoperative and postoperative plasma mSEPT9 reflected the therapeutic efficacy of curatively intended surgery for CRC patients. The persistent positivity of plasma mSEPT9 after surgery (within 7–14 days) was highly associated with impending recurrences or metastases (within one year), with a sensitivity of 100%. Postoperative mSEPT9 status during follow-up also provided valuable indication for CRC recurrence or metastases, with a good consistency (kappa = 0.818, P = 0.001). Our results verified the reliability of plasma mSEPT9 as a biomarker for noninvasive diagnosis of CRC. More significantly, we revealed its valuable role in appraising CRC therapeutic efficacy and monitoring CRC recurrences or metastases. Further studies with larger sample sizes are needed to verify and elucidate the clinical utility of the promising findings.
登录
查看更多内容
影响因子：
11
作者：
Al-Shuneigat JM;Mahgoub SS;Huq F
通讯作者：
Huq F
影响因子：
3.5
作者：
Mitchell SM;Ho T;Brown GS;Baker RT;Thomas ML;McEvoy A;Xu ZZ;Ross JP;Lockett TJ;Young GP;LaPointe LC;Pedersen SK;Molloy PL
通讯作者：
Molloy PL
个体化多重循环肿瘤 DNA 检测，用于监测结直肠癌手术后患者肿瘤的存在。
影响因子：
4.6
作者：
Ng SB;Chua C;Ng M;Gan A;Poon PS;Teo M;Fu C;Leow WQ;Lim KH;Chung A;Koo SL;Choo SP;Ho D;Rozen S;Tan P;Wong M;Burkholder WF;Tan IB
通讯作者：
Tan IB
影响因子：
2.9
作者：
Allemani C;Rachet B;Weir HK;Richardson LC;Lepage C;Faivre J;Gatta G;Capocaccia R;Sant M;Baili P;Lombardo C;Aareleid T;Ardanaz E;Bielska-Lasota M;Bolick S;Cress R;Elferink M;Fulton JP;Galceran J;Gózdz S;Hakulinen T;Primic-Zakelj M;Rachtan J;Diba CS;Sánchez MJ;Schymura MJ;Shen T;Tagliabue G;Tumino R;Vercelli M;Wolf HJ;Wu XC;Coleman MP
通讯作者：
Coleman MP
影响因子：
5
作者：
Lee, Hye Seung;Hwang, Sang Mee;Park, Kyoung Un
通讯作者：
Park, Kyoung Un